Volume 18, Number 6—June 2012
CME ACTIVITY - Synopsis
Iatrogenic Creutzfeldt-Jakob Disease, Final Assessment
Table 2
Source of Infection | No. cases | Mean incubation period, y (range) | Clinical signs† |
---|---|---|---|
Dura mater graft | 228 | 12 (1.3–30) | Cerebellar, visual, dementia |
Neurosurgical instruments | 4 | 1.4 (1–2.3) | Visual, dementia, cerebellar |
Stereotactic EEG needles | 2 | 1.3, 1.7 | Dementia, cerebellar |
Corneal transplant | 2 | 1.5, 27 | Dementia, cerebellar |
Growth hormone | 226 | 17 (5–42)‡ | Cerebellar |
Gonadotropin | 4 | 13.5 (12–16) | Cerebellar |
Packed red blood cells§ | 3 | 6.5, 7.8, 8.3 | Psychiatric, sensory, dementia, cerebellar |
*EEG, electroencephalogram.
†In order of decreasing frequency.
‡Averages and ranges were 13 (5–24) y in France; 20 (7–39) y in the United Kingdom; and 22 (10–42) y in the United States.
§An additional asymptomatic but infected red-cell recipient died of an unrelated illness; another asymptomatic infected hemophilia patient who had been exposed to potentially contaminated factor VIII also died of an unrelated illness (neither is included in the table).
Page created: May 17, 2012
Page updated: May 17, 2012
Page reviewed: May 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.